[go: up one dir, main page]

AU777012B2 - Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist - Google Patents

Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist Download PDF

Info

Publication number
AU777012B2
AU777012B2 AU67016/00A AU6701600A AU777012B2 AU 777012 B2 AU777012 B2 AU 777012B2 AU 67016/00 A AU67016/00 A AU 67016/00A AU 6701600 A AU6701600 A AU 6701600A AU 777012 B2 AU777012 B2 AU 777012B2
Authority
AU
Australia
Prior art keywords
medicament
adrenoceptor agonist
oxide
pharmacologically tolerable
roflumilast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU67016/00A
Other versions
AU6701600A (en
Inventor
Rolf Beume
Daniela Bundschuh
Armin Hatzelmann
Ulrich Kilian
Christian Schudt
Christian Weimar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of AU6701600A publication Critical patent/AU6701600A/en
Assigned to ALTANA PHARMA AG reassignment ALTANA PHARMA AG Amend patent request/document other than specification (104) Assignors: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Application granted granted Critical
Publication of AU777012B2 publication Critical patent/AU777012B2/en
Assigned to NYCOMED GMBH reassignment NYCOMED GMBH Request to Amend Deed and Register Assignors: ALTANA PHARMA AG
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: NYCOMED GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: TAKEDA GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Seasonings (AREA)
  • Inorganic Insulating Materials (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
  • Piezo-Electric Or Mechanical Vibrators, Or Delay Or Filter Circuits (AREA)
  • Lubricants (AREA)

Abstract

The invention relates to the combined administration of PDE inhibitors and ² 2 adrenoceptor agonists for the treatment of respiratory tract disorders.

Description

-1- Synergistic combination Field of application of the invention The invention relates to the combination of certain known active compounds for therapeutic purposes.
The substances used in the combination according to the invention are known active compounds from the PDE inhibitors class and active compounds from the 32 adrenoceptor agonists class. Their combined use in the sense according to the invention for therapeutic purposes has not yet been described in the prior art.
Description of the invention It is the object of the present invention to make available respiratory tract therapeutics which fulfill the following conditions: Good antiinflammatory action Marked bronchorelaxation and -dilatation Good oral availability, at least with respect to the PDE inhibitor Minor side effects Good suitability for long-term therapy Favorable influence on bronchial hyperreactivity.
25 It has now been found that the combined use of certain specific PDE inhibitors which can be used as a respiratory tract therapeutic and of a p2 adrenoceptor agonist outstandingly fulfills the abovementioned conditions.
The invention thus relates to the combined use of a PDE inhibitor chosen from a 30 particular group which can be used as a respiratory tract therapeutic and a p2 **adrenoceptor agonist in the treatment of respiratory tract disorders.
i* e PDE inhibitors which can be used as respiratory tract therapeutics in the sense of the present invention are compounds which slow the breakdown of cyclic AMP (cAMP) or cyclic GMP (cGMP) by inhibition of the phosphodiesterases, which can lead to a relative increase in the intracellular concentration of cAMP or cGMP.
\\melb-files\homeS\susanp\keep\ALTANA PHARMA 67016-OO.doc 5/08/04 -2- Possible PDE inhibitors within the meaning of the present invention and specified in the claims are to be considered part of the PDE4 inhibitor class or can be designated as mixed types of PDE3/4 inhibitors. Also within these classes which may be mentioned are the PDE inhibitors described or claimed in the following patent applications and patents: DE 1545687, DE 2028869, DE 2123328, DE 2315801. DE 2402908, D 941Q'_ nF q.qn PP nl'"A1-47, :p n1o34A, CM 045a330, EP 0163965, EP 0335386, EP 0389282, EP 0428302, EP 0435811, EP 0459505, EP 0470805, EP 0490823, EP 0506194, EP 0511865, EP 0527117, EP 0557016, EP 0626939, EP 0664289, EP 0671389, EP 0685474, EP 0685475, EP 0685479, EP 0736532, EP .0 0738715, EP 0748805, EP 0763534, EP 0816357, EP 0819688, EP 0819689, EP 0832886, EP 0834508, EP 0848000, JP 92234389, JP 94329652. JP 95010875, JP 98072415, JP 98147585, US 5703098, US 9307146, WO 9315044, WO 9319747, WO 9319749, WO 9420455, WO 9422852, WO 9504045, WO 9504046, WO 9509627, WO 9509836, WO 9517399, WO 9519362, WO 9535281, WO 9535283, WO 9611690, WO 9611917, WO 20 9636595, WO 9636596,
WO
9639408, WO 9640636, WO 9709345, WO 9712895, WO 9722586, WO 9723457, WO 9725312, WO 9728131, WO 9736905, WO 9743288, WO 9804534, WO 9805327, WO 9808830, WO 9808841, WO 9814448, WO 9818796, WO 5739144, WO 9315045, WO 9319751, WO .9427947, WO 9505386, WO 9514667, WO 9520578, WO 9535284, WO 9612720, WO 9636611, WO 9703967, WO 9718208, WO 9723460, WO 9730999, WO 9744036, WO 9806692, WO 9808844, WO 9821208, WO 9117991, WO 9318024, WO 9325517. WO 9501338, WO 9508534, WO 9514680, WO 9522520, WO 9600218, WO 9631486, WO 9636625, WO 9704779, WO 9719078, WO 9723461, WO 9731000, WO 9744322, WO 9806704, WO 9809946, WO 9822453, WO 9200968, 9319068, 9402465, 9501980, 9509623, 9514681, 9524381, 9601825, 9631487, 9636638, 9705105, 9720833, 9724117, 9732853, 9747604, 9807715, 9809961, 9845268,
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
9212961, 9319720, 9412461, 9503794, 9509624, 9517392, 9527692, 9606843, 9635683, 9638150, 9708143, 9722585, 9724355, 9735854, 9748697, 9808828, 9811113, 9855481,
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
WO
9 *ooo *oooo o9o .9o 90 9 9856756, WO 9905111, WO 9905112, WO 9505113, WO 9906404 and WO 9918095. Those PDE inhibitors are to be emphasized which are claimed in the patent applications or patents 30 EP 0393500, EP 0510562, EP 0553174, WO 9501338, WO 9603399, WO 9636625, WO 9636626, WO 9735854, WO 9821208, WO 9831674, WO 9840382, WO 9855481, WO 9905111, WO 9905112, WO 9905113, WO 9931071 and WO 9931090. Substances having good oral availability are preferred here.
Exemplary PDE inhibitors are shown on the following pages with the aid of theIr formulae: \\melb-files\home$\susanp\keep\ALTANA PHARMA 67016-00.doc 5/08/04 WO 01/13953 WO 0113953PCr/EP00107952 CI y N z1 0I N
-N
Ck~ I >-r 0 0 S -N
I-I
Br
N-.
0
NT
N NO0 N N 01, 0 0~ 0i X 0 0-
N
00 N-.N
N
6 CI N C 0* F><F 0 WO 01/13953 PTEOI7S PCT/EPOO/07952 0 0 00 Cr 0 C N lC I w- 0 0 0 00 01 &l cr 0 o ci' 0 NNO 0 0 0-0)0-i -o0.
NO 0 WO 01/13953 WO 0113953PCT/EPOO/07852 0 N 0 0~ 0
NN
0 N0 00
N'N
0 0 0~ N, 0 0 00 0 A 0 C 0 0 N;
O
0 0~ 00 00 s 0 0~ 0 0 0 0
N-N
~c 0 ~r
N
N
0 0~i N 0 z z 0 0 z 0=8 z -i 00$o 0\ z 0
Z
0 00 0 0o 0 u0 z' If 0 0 Z
U.
C
0 z 0 0 0 0 z 0 0o- 0- 0 0z' flea n.~.1flEi VVIJ Uj1137J3 PCTIFPflAJfl7R~7
NN
N s NN N s s 0. NS N N CN F 0 0&
N
1 ,N 0A L 0l F 0 s 0
\N
N) aN' WO 01/13953PC/PO0821 PCT/EPOO/07852 0
N-
N~
c/A 0, N I N/ 0 6 W001/13953 1 N 0 0
N.
N
-N.
0 0 A A 0 0NI PCTIEPOOIO7852 WOO01 /13953 12 00 ozz
N
0- N I1 N. 0 N
N
-N
N 1 II~N~0 0 N N. 0 O'N' y.
'N0 NN 00
NH
0 k. l PCT/EPOO/07852 BYK-33043 (Pumafentrin) WO 01/13953 PCTIEPOO/07852 0 0 0~<N N N-0 U 0
N
0 N f c I N 0
NN
0N
N
0 N N N N 0
S
o N 0 0! N N
I
Roflumilast WO 01/13953 PCT/EPOO/07852 14 0 N CI 0o 0
N
IN0 -00 0 0 0 00: ~O~y~Ny~N 0 0 0 AN
NN
N) N N N 0 N N~ 0- No hydrogen atoms are indicated in the above formulae. -0 is accordingly-OH, -N is NH 2 Methyl groups, e.g. on the oxygen atoms, are indicated by lines.
PDE inhibitors to be emphasized which are selected from the abovementioned compounds and which may be mentioned are the active compounds arofylline, atizoram, AWD-12-281, BAY-19-8004, benafentrine, BYK-33043, CC-3052, CDP-840, CI-1018, cipamfylline, CP- 220629, CP-293121. D-22888, D-4396, D-4418, denbufylline, filaminast, GW-3600, ibudilast, 20 KF-17625, KS-506-G, laprafylline, NA-0226A, NA-23063A, ORG-20241, ORG-30029, PDB- 093, pentoxifylline, piclamilast, rollumilast, rolipram, RPR-117658, RPR-122818, RPR- 132294, RPR-132703, RS-117597, RS-25344-O00, SB-207499, SB-210667, SB-2111572, SB- *.**211600, SB-212066, SB-212179, SDZ-ISQ-844, SDZ-MNS-949, SKIF-107806, SQ-20008, T- 2585, T-440, tibenelast, tolafentrine, UCB-29646, V-I 1294A, YM-58997, YM-976 and zardaverine.
.6 The compounds preferred from the group of the abovementioned PODE inhibitors are :-:arofylline, cipamfylline, D-4418, filaminast, ibudilast, laprafylline, ORG-20241, piclamilast, rolipram, SB-207499, tibenelast and V-i 1 294A. The compounds particularly preferred are 3 0 BYK-33043 and in particular roflumilast, and thus these two compounds are the subject of the presently claimed invention.
02 adrenoceptor agonists which may particularly be mentioned are those selectively acting substances which only have a slight cardiac action and therefore are also employed in 3 5 therapy, in particular in the oral therapy of respiratory tract disorders. P32 adrenoceptor agonists which may be mentioned are, for example: AR-C68397AA, broxaterol, CHF-1 035, \\melb~files\home\susanp\keep\A.LTAJA PHARMA 67016-00doc 5/08/04 -16- HOKU-81, ibuterol, KUL-1248, soterenol, meluadrine, TA-2005, tiaramide, salbutamol, levosalbutamol, tulobuterol, terbutaline, carbuterol, pirbuterol, reproterol, clenbuterol, fenoterol, hexoprenaline, orciprenaline, isoprenaline, formoterol, salmeterol, rimiterol, procaterol, bambuterol, bitolterol and mabuterol. The orally readily available p adrenoceptor agonists such as clenbuterol, orciprenaline, salbutamol, terbutaline, tulobuterol, bambuterol and reproterol are preferred. Particularly preferred are the so-c! d l ong acting p adrenoceptor agonists, such as salmeterol.
The PDE inhibitors and the P2 adrenoceptor agonists can be present as such or in chemically bonded form. It is understood hereby that the active compounds mentioned can also be present, for example, in the form of their pharmacologically tolerable salts and/or as solvates hydrates), and/or in the form of their N-oxides etc. Suitable pharmacologically tolerable salts here are in particular water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 1-hydroxy-2-naphthoic acid, the acids being employed in salt preparation depending on whether it is a mono- or polybasic acid and depending on which salt is desired in an equimolar quantitative ratio or one differing therefrom. Furthermore, the 20 active compounds mentioned can also be present as pure enantiomers or as enantiomer mixtures in any mixing ratio.
Respiratory tract disorders which may be mentioned are in particular allergen- and inflammation-Induced bronchial disorders (bronchitis, obstructive bronchitis, spastic 25 bronchitis, allergic bronchitis, allergic asthma, bronchial asthma, COPD), which can be treated by the combination according to the invention also in the sense of a long-term therapy (if desired with appropriate adjustment of the dose of the individual components to the needs at the time, for example needs subject to seasonally related variations).
S30 "Combined use" or "combination" within the meaning of the present invention is to be o. understood as meaning that the individual components can be administered simultaneously (in the form of a combination medicament i.e. fixed combination), more or less simultaneously (from separate pack units or in succession (directly in succession or else alternatively at a relatively large time interval) in a manner which is known per se and customary.
\\melbfies\home\ssanp\keep\ALTANA PHARP A 67016-00.doc 5/08/04 16a- Within the meaning of the present invention, "use" is preferably understood as meaning the oral administration of both active compounds. If only the PDE inhibitor is administered orally, "use" with respect to the 32 adrenoceptor agonist is understood in particular as meaning.
\\melbfiles\homeS\susanp\keep\ALTANA PHARMA 67016-00.doc 5/08/04 WO 01/13953 PCT/EPOO/07852 topical application in inhalatory form. For this, the 32 adrenoceptor agonist is preferably administered by inhalation in the form of an aerosol, the aerosol particles of solid, liquid or mixed composition having a diameter of 0.5 to 10 pm, advantageously of 2 to 6 pm.
Aerosol generation can be carried out, for example, by pressure-driven jet atomizers or ultrasonic atomizers, but advantageously by propellant-driven metered aerosols or ornnAllant-free administration of micronized active compounds from inhalation caps.ules.
The active compounds are dosed in an order of magnitude customary for the individual dose, it more likely being possible, on account of the individual actions, which are mutually positively influencing and reinforcing, to reduce the respective doses on the combined administration of the active compounds compared with the norm. Customarily, the 32 adrenoceptor agonist (depending on potency) is administered in a dose of, for example, 0.002 to 2.0 mg per day on administration by inhalation.
Depending on the inhaler system used, in addition to the active compounds the administration forms additionally contain the required excipients, such as, for example, propellants Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers lactose in the case of powder inhalers) or, if appropriate, further active compounds.
For the purposes of inhalation, a large number of apparatuses are available with which aerosols of optimum particle size can be generated and administered, using an inhalation technique which is as right as possible for the patient. In addition to the use of adaptors (spacers, expanders) and pear-shaped containers Nebulator®, Volumatic@), and automatic devices emitting a puffer spray (Autohaler®), for metered aerosols, in particular in the case of powder inhalers, a number of technical solutions are available Diskhaler®, Rotadisk®, Turbohaler@ or the inhaler described in European Patent Application EP 0 505 321), using which an optimal administration of active compound can be achieved.
In the case of the oral administration of the P2 adrenoceptor agonists together with the PDE inhibitor, which is the preferred administration form, the 32 adrenoceptor agonist is administered in a daily dose of, for example, 0.05 to 60 mg. For the PDE inhibitors, it is possible in the case of oral administration to vary the doses depending on the active compound within a wide range, it being possible, as bounds, to start from a dose of 1 2000 pg/kg of body weight. In the case of the administration of the preferred PDE inhibitor roflumilast, the dose is in the range from 2 20 pg/kg of body weight.
The PDE inhibitors to be administered orally are formulated if appropriate together with the 02 adrenoceptor agonists to give medicaments according to processes known per se and WO 01113953 PCT/EP00/07852 familiar to the person skilled in the art. The pharmacologically active compounds are employed as medicaments, preferably in combination with suitable pharmaceutical excipients or vehicles, in the form of tablets, coated tablets, capsules, emulsions, suspensions or solutions, the active compound content advantageously being between 0.1 and 95% and, by the appropriate choice of the excipients and vehicles, it being possible to achieve a pharmaceutical administration form precisely tailored to the active compound(s) and/or to the desird nn.st of actinn (e a sustained-release form or an enteric form). Paricu!adry worthy of mention within the meaning of the combined, oral administration of both active compounds according to the invention are oral administration forms, e.g. tablets or capsules, in which one part of the 32 adrenoceptor agonist and the PDE inhibitor is present in non sustainedrelease form and a further, preferably larger part, of thep32 adrenoceptor agonist is present in sustained-release form.
The person skilled in the art is familiar on the basis of his/her expert knowledge with which excipients or vehicles are suitable for the desired pharmaceutical formulations. In addition to solvents, gel-forming agents, tablet excipients and other active compound carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, colorants or permeation promoters and complexing agents cydodextrins).
~~nZ~ PrT/rpnO/07R2 WOu0111395 19 WUUIIJYJ3 19 Pharmacology Model Late Inflammatory Airway Reaction in the Ovalbumin-sensitizedl-challenged Brown-Norway Rat Anti-inflammatory activity of Roflumilast, Pumafentrine (BYK-33043), and Salmeterol was determined in ovalbumin (OVA)-sensitized and OVA-challenged Brown Norway rats. Sensitization was done by simultaneous injection of Bordetella pertussis suspension i.p. and OVA/AHG suspension s.c. on day 1, 14 and 21. 28 days after start of sensitization, conscious Brown-Norway rats were challenged by inhalation of the aerosolized OVA solution for 1 h (-20 mlh). Non-challenged, only sensitized animals were used as baseline control. The drugs (thoroughly mixed with lactose) or the placebo control (lactose) were administered intratracheally as dry powders 1 h before OVA-challenge. 48h later, OVA-challenged or non-challenged animals were anaesthetized and bronchoalveolar lavage (BAL) was performed using 3x4 ml BAL buffer per animal. The number of total cells and eosinophils in the BAL fluid, and the concentration of protein in the cell-free BAL fluid were determined. Drug-induced relative changes were calculated and statistically analyzed by the Jonckheere Terpstra test.
Results Compound PDE3/4 Dose Appl. N Inhibition of Infiltration/Accumulation [pmol/kg Route [Median SMean SEM] Total cells EOS Protein Roflumilast >10/0.0007 0.3 it 8 -25 -15 -8 -37.6±26.7 -22±25.7 -22.3±25.5 Pumafentrine 0.028/0.007 3 it 8 -19 -26 17 -39.1 30.5 -28.5±30.1 23.5±10.6 Salmeterol 3 it 8 19 39 44 6.3±17.9 31±14.8 37.5±16.2 Salmeteroll 3/0.3 it 8 50 67 59* Roflumilast 34.5±21.1 61.1±7.9 50.8±13.6" Salmeterol/ 3/3 it 8 56 85 Pumafentrine 58.1±12.3 83±3.7 67.1±11.1 0.05, p< 0.01 v.s. untreated, OVA-challenged control groups Summary The PDE inhibitors Roflumilast (PDE4 inhibitor) and Pumafentrine (PDE3>4 inhibitor) administered at doses of 0.3 pmol/kg and 3 pmolkg respectively, did not show any significant effects on cell infiltration and protein accumulation. The negative values obtained (trend: amplification of inflammation) fall into the range of biological variability of the model and therefore, no significance must be attached to these data.
In contrast, the long-acting p 2 -adrenergic receptor agonist Salmeterol given at a dose of 3 gmolkg i.t. exhibited inhibitory effects on total cell and eosinophil influx into alveolar space and protein levels in BAL fluid. However, the data failed to reach significance.
Co-administration of the PDE inhibitor Rofiumilast or Pumafentrine with Salmeterol resulted in synergisitc effects compared to administration of every compound alone, i.e. both PDE inhibitors combined with the p2 agonist displayed a significant inhibition of eosinophilia and reduction of protein concentration in the BAL fluid. The combination of the PDE3/4 inhibitor Pumafentrine and Salmeterol was more efficacious on all parameters measured (difference was not significant), and additionally, showed a significant effect on inhibition of total cell influx into the alveolar space.
In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
\\melbfies\home\susanp\keep\ALTANA PHARMA 67016-OO.doc 5/08/04

Claims (10)

1. A medicament comprising a PDE inhibitor, which is to be administered orally, from the PDE4 or PDE3/4 inhibitors group combined with a 32 adrenoceptor agonist in fixed or free combination, wherein the PDE inhibitor is roflumilast, its pharmacologically tolerable sail and/or its N-oxide, or wherein the PDE inhibitor is pumafentrine, its pharmacologically tolerable salt and/or its N-oxide.
2. The medicament as claimed in claim 1, which is a fixed oral combination.
3. The medicament as claimed in claim 1 or 2 for use in the therapeutic treatment of respiratory tract disorders.
4. The medicament as claimed in claim 1 or 2, wherein the PDE inhibitor is roflumilast, its pharmacologically tolerable salt and/or its N-oxide. The medicament as claimed in claim 1 or 2, wherein the PDE inhibitor is pumafentrine, its pharmacologically tolerable salt and/or its N-oxide. 20 6. The medicament as claimed in claim 1 or 2, wherein the PDE inhibitor is roflumilast, its pharmacologically tolerable salt and/or its N-oxide and the 32 adrenoceptor agonist is salmeterol or a pharmacologically tolerable salt thereof.
7. The medicament as claimed in claim 1 or 2, wherein the PDE inhibitor is pumafentrine, its pharmacologically tolerable salt and/or its N-oxide and the P2 adrenoceptor agonist is salmeterol or a pharmacologically tolerable salt thereof. *o
8. The medicament as claimed in claim 1 or 2, wherein the 32 adrenoceptor agonist is clenbuterol, orciprenaline, salbutamol, terbutaline, tulobuterol, bambuterol or 30 reproterol or a pharmacologically tolerable salt thereof.
9. The medicament as claimed in claim 1 or 2, wherein the PDE inhibitor is roflumilast or pumafentrine, their salts and/or their N-oxides and the 32 adrenoceptor agonist is clenbuterol, orciprenaline, salbutamol, terbutaline, tulobuterol, bambuterol or reproterol or a pharmacologically tolerable salt thereof. \\melb-files\homeS\s.sanp\keep\ALTANA PHARMA 67016-00.doc 5/08/04 -22- The use of roflumilast or pumafentrine for the production of a medicament, which is to be administered orally, in combination with a 32 adrenoceptor agonist in the therapeutic treatment of respiratory tract disorders.
11. The use of a P2 adrenoceptor agonist for the production of a medicament for oral administration in combination with roflumilast or pumafentrine in the therapeutic treatment of respiratory tract disorders.
12. A method for the treatment of respiratory tract disorders, comprising oral administration of roflumilast, its salt and/or its N-oxide, or pumafentrin, its salt and/or its N-oxide, in fixed or free combination with a P2 adrenoceptor agonist.
13. A medicament, use of compounds for the production of a medicament, or method for the treatment of respiratory tract disorders, substantially as herein described with reference to the accompanying Examples. Dated this 5th day of August 2004 SALTANA Pharma AG 20 By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia *o g* *•o \\mel~bfiles\home\susanp\keep\ALTANA PHARA 67016-OO.doc 5/08/04
AU67016/00A 1999-08-21 2000-08-11 Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist Ceased AU777012B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99116447 1999-08-21
EP99116447 1999-08-21
PCT/EP2000/007852 WO2001013953A2 (en) 1999-08-21 2000-08-11 Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist

Publications (2)

Publication Number Publication Date
AU6701600A AU6701600A (en) 2001-03-19
AU777012B2 true AU777012B2 (en) 2004-09-30

Family

ID=8238828

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67016/00A Ceased AU777012B2 (en) 1999-08-21 2000-08-11 Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist

Country Status (28)

Country Link
US (3) US7056936B2 (en)
EP (3) EP1671651B1 (en)
JP (1) JP5038568B2 (en)
KR (1) KR100701904B1 (en)
CN (1) CN1202865C (en)
AT (2) ATE320800T1 (en)
AU (1) AU777012B2 (en)
BR (1) BRPI0013478B8 (en)
CA (2) CA2381802C (en)
CZ (1) CZ302882B6 (en)
DE (2) DE60043318D1 (en)
DK (1) DK1212089T3 (en)
EA (1) EA006685B1 (en)
ES (1) ES2260043T3 (en)
HK (1) HK1047244B (en)
HR (1) HRP20020158B1 (en)
HU (1) HU229439B1 (en)
IL (2) IL147688A0 (en)
MX (1) MXPA02001830A (en)
NO (1) NO328340B1 (en)
NZ (1) NZ517166A (en)
PL (1) PL200923B1 (en)
PT (1) PT1212089E (en)
SI (1) SI1212089T1 (en)
SK (1) SK287231B6 (en)
TR (2) TR200909479T2 (en)
WO (1) WO2001013953A2 (en)
ZA (1) ZA200201389B (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090076A1 (en) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (en) 2001-03-22 2008-01-15 Glaxo Group Ltd FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
KR20040007596A (en) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 Compositions for promoting healing of bone fracture
US20040180900A1 (en) * 2001-05-23 2004-09-16 Masaharu Takigawa Therapeutic composition for repairing chondropathy
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
IL160272A0 (en) * 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing a pde4 or a pde3/4 inhibitor and a leukotriene receptor antagonist
AU2002337105B2 (en) * 2001-09-19 2008-03-20 Takeda Gmbh Combination of a NSAID and a PDE-4 inhibitor
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
GB0129395D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
WO2003051344A1 (en) * 2001-12-14 2003-06-26 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation_using a non-polypeptide camp level modulator
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ATE381535T1 (en) 2002-04-25 2008-01-15 Glaxo Group Ltd PHENETHANOLAMINE DERIVATIVES
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
PL216752B1 (en) * 2002-11-27 2014-05-30 Nycomed Gmbh New synergistic combination comprising roflumilast and formoterol
CA2506956C (en) * 2002-11-27 2012-10-02 Altana Pharma Ag Synergistic combination comprising roflumilast and (r,r)-formoterol
WO2004062671A2 (en) * 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
HRP20050399B1 (en) 2003-03-10 2013-09-30 Takeda Gmbh Novel process for the preparation of roflumilast
WO2004087151A1 (en) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co., Ltd. Medicinal composition
CN1812983A (en) * 2003-05-30 2006-08-02 兰贝克赛实验室有限公司 Substituted pyrrole derivatives and their use as hmg-co inhibitors
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (en) 2004-10-22 2006-04-24 Novartis Ag ORGANIC COMPOUNDS.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR059838A1 (en) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd FORMULATIONS FOR STABILIZING DOSES OF STATIN
RU2457209C2 (en) 2006-04-21 2012-07-27 Новартис Аг Purine derivatives applicable as adenosine receptor a2a agonists
US20100029681A1 (en) * 2006-05-26 2010-02-04 Hassan Pajouhesh Heterocyclic compounds as calcium channel blockers
TWI436761B (en) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd Methods of using a thiazole derivative
CL2007002044A1 (en) * 2006-07-14 2008-06-13 Ranbaxy Lab Ltd CRYSTALLINE POLYMORPH OF HEMICALCIC ACID SALT (3R, 5R) -7- [2- (4-FLUOROPHENYL) -5-ISOPROPIL-3-PHENYL-4 - [(4-HYDROXIMETHYLPHENYLAMINE) CARBON]] -PIRROL-1-IL] -3,5-DIHYDROXIHEPTANOIC; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DIABETES, ENF
MX2009003185A (en) 2006-09-29 2009-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors.
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
HRP20110201T1 (en) 2007-01-10 2011-08-31 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS OF CANALIZED ACTIVATION
DE602008005140D1 (en) 2007-05-07 2011-04-07 Novartis Ag ORGANIC CONNECTIONS
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
AR069637A1 (en) 2007-12-10 2010-02-10 Novartis Ag PIRAZINE DERIVATIVES
CN101910153B (en) 2008-01-11 2014-01-22 诺华股份有限公司 Pyrimidines as Kinase Inhibitors
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
PT2391366E (en) 2009-01-29 2013-02-05 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (en) 2009-08-12 2016-05-17 Novartis Ag Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
PE20121148A1 (en) 2009-08-17 2012-09-07 Intellikine Llc HETEROCYCLIC COMPOUNDS AND USES OF THEM
BR112012008061A2 (en) 2009-08-20 2016-03-01 Novartis Ag heterocyclic oxime compounds
JP2013508414A (en) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Compositions for the treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33373A (en) 2010-05-10 2011-12-30 Gilead Sciences Inc ? Bifunctional pyrazolopyridine compounds, their use in therapy and compositions that comprise them ?.
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2012022796A2 (en) * 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Novel combinations
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012098495A1 (en) * 2011-01-19 2012-07-26 Glenmark Pharmaceuticals Sa Pharmaceutical composition that includes revamilast and a beta-2 agonist
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
BR112013021638A2 (en) 2011-02-25 2016-08-02 Irm Llc "trk inhibiting compounds, their use and compositions comprising them"
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
CN103946221B (en) 2011-09-16 2016-08-03 诺华股份有限公司 Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (en) 2011-09-16 2021-12-02 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013081565A1 (en) * 2011-11-21 2013-06-06 Mahmut Bilgic Pharmaceutical compositions comprising roflumilast and terbutaline
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (en) 2012-04-03 2015-04-27 ノバルティス アーゲー Combination products with tyrosine kinase inhibitors and their use
CN103830236A (en) * 2012-11-21 2014-06-04 岳阳新华达制药有限公司 Bambuterol hydrochloride and roflumilast compound preparation and its preparation method
SI2948148T1 (en) * 2013-01-28 2020-12-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CN106458979B (en) 2014-04-24 2020-03-27 诺华股份有限公司 Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
EP3134396B1 (en) 2014-04-24 2019-09-18 Novartis AG Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016023967A2 (en) 2014-04-24 2017-08-15 Novartis Ag pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
JOP20190219A1 (en) * 2017-05-09 2019-09-22 Cardix Therapeutics LLC Pharmaceutical compositions and methods of treating cardiovascular diseases
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
PE20220346A1 (en) 2019-08-28 2022-03-14 Novartis Ag 1,3-HETEROARYL SUBSTITUTED DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
TW202325275A (en) 2021-10-29 2023-07-01 美商感覺中樞治療公司 Delivery of therapeutic alkaloid compounds
WO2025188807A1 (en) * 2024-03-06 2025-09-12 Curasen Therapeutics, Inc. Combination compositions and methods of use

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545687B2 (en) 1964-09-05 1975-09-04 Hoechst Ag, 6000 Frankfurt 1- (5'-Oxohexyl) -3,7-dimethylxanthine and process for its preparation
CA924721A (en) 1969-06-16 1973-04-17 Chasin Mark Hydrazines and hydrazones of pyrazolopyridine carboxylic acids and esters
GB1361441A (en) 1970-05-13 1974-07-24 Sandoz Ltd Benzonaphthyridine derivatives
BE791025A (en) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd HETEROCYCLIC COMPOUNDS
JPS5229318B2 (en) 1972-03-30 1977-08-01
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DE2462367A1 (en) 1974-01-22 1976-11-11 Wuelfing J A Fa 7-(Oxo-alkyl)-1,3-dialkyl-xanthines - as agents for increasing blood flow in skeletal muscles
DE2413935A1 (en) 1974-03-20 1975-10-16 Schering Ag 4- (POLYALCOXY-PHENYL) -2-PYRROLIDONE
FR2390164A1 (en) * 1977-05-13 1978-12-08 Blanie Paul Anti:asthmatic methyl-xanthine compsns. - synergised with beta-sympathomimetic agents
DE2847693A1 (en) * 1978-11-03 1980-05-22 Hoechst Ag METHOD FOR PRODUCING PYRIMIDO- (6,1-A) -ISOCHINOLIN-2-ONES
FR2531085A1 (en) 1982-07-28 1984-02-03 Adir NOVEL XANTHINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4552891A (en) 1983-09-13 1985-11-12 Eli Lilly And Company Benzothiophene derivatives
GB8406906D0 (en) 1984-03-16 1984-04-18 Akzo Nv Benzo-thiazole and benzothiophene derivatives
DK159431C (en) 1984-05-10 1991-03-18 Byk Gulden Lomberg Chem Fab 6-PHENYL-3 (2H) -PYRIDAZINONES, METHOD OF PREPARING THEREOF, PHARMACEUTICALS CONTAINING THESE AND USING THE COMPOUNDS FOR THE PREPARATION OF MEDICINAL PRODUCTS
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5142096A (en) 1988-03-31 1992-08-25 Kyowa Hakko Kogyo Co., Ltd. 2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
EP0469013B1 (en) 1989-04-17 1995-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel arylpyridazines, their manufacture, use and medicaments containing them
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
CZ280006B6 (en) 1989-11-13 1995-09-13 Pfizer Inc. Process for preparing optically active (2s) or (2r)-endobicyclo£2.2.1|hepan-2-ole
GB8929208D0 (en) 1989-12-27 1990-02-28 Almirall Lab New xanthine derivatives
MY105344A (en) 1990-05-16 1994-09-30 Byk Gulden Lomberg Chemische Fabrik New sulphonyl compounds
EP0459505B1 (en) 1990-06-01 1996-10-02 Kyowa Hakko Kogyo Co., Ltd. Imidazonaphthyridine derivatives
FI930077L (en) 1990-07-10 1993-01-08 Smithkline Beecham Corp OXAMIDER
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
JPH06501941A (en) 1990-10-16 1994-03-03 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング Arylpyridazinone
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
JPH04234389A (en) 1990-12-28 1992-08-24 Sapporo Breweries Ltd Naphthyridine derivative and antiulcer agent containing the derivative as active component
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
IE73235B1 (en) 1991-03-25 1997-05-21 Akzo Nv 4-aryl-thiazole or imidazole derivatives
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
EP0581805A1 (en) 1991-04-26 1994-02-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyridazines
US5191084A (en) 1991-05-01 1993-03-02 American Home Products Corporation Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents
GB9116039D0 (en) 1991-07-25 1991-09-11 Ucb Sa Substituted cyclopropylamino-1,3,5-triazines
KR100263494B1 (en) 1991-10-09 2000-08-01 헤르빅 폰 모르체 Benzo and pyrido pyridazinone and pyridazinthione compounds with pde iv inhibiting activity
WO1993015045A1 (en) 1992-01-29 1993-08-05 Smithkline Beecham Corporation N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
AU3588693A (en) 1992-01-29 1993-09-01 Smithkline Beecham Corporation N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as TNF and PDE IV inhibitors
JP3042156B2 (en) 1992-02-20 2000-05-15 田辺製薬株式会社 Naphthalene derivative, its production method and its synthetic intermediate
GB9204808D0 (en) 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
US5264437A (en) 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
JP3199380B2 (en) 1992-04-02 2001-08-20 スミスクライン・ビーチャム・コーポレイション Compound
JP3251587B2 (en) 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション Compounds useful for treating inflammatory diseases and inhibiting tumor necrosis factor production
MX9301903A (en) 1992-04-02 1994-08-31 Smithkline Beecham Corp COMPOUNDS.
JP3634861B2 (en) 1992-06-15 2005-03-30 セルテック リミテッド Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
JP3775684B2 (en) 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Phenyl-containing compounds linked to an aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
TW263495B (en) 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5455252A (en) 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
GB9309324D0 (en) 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
GB9311282D0 (en) 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd New compositions of matter
JPH0710875A (en) 1993-06-21 1995-01-13 Green Cross Corp:The Selective phosphodiesterase IV inhibitors
CN1046939C (en) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
BR9406946A (en) 1993-07-06 1996-08-06 Pfizer Bicyclic tetrahydro-pyrazolpyridines
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
DE69430747T2 (en) 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling CONNECTIONS AS PDE IV AND TNF INHIBITORS
EP0714293A4 (en) 1993-07-30 1999-04-07 Smithkline Beecham Corp 3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates
US5812241A (en) 1993-08-19 1998-09-22 Block Medizintechnik Gmbh Compact refractor for subjective examination of human eyes
EP0714397A1 (en) 1993-08-19 1996-06-05 Smithkline Beecham Corporation Phenethylamine compounds
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
EP0727990B1 (en) 1993-10-01 2001-06-13 Smithkline Beecham Corporation Compounds, compositions and treatment of allergies and inflammation
WO1995009623A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Anti-allergic, anti-inflammatory compounds, compositions and uses
WO1995009836A1 (en) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Cyanocyclohexane compounds, compositions, and uses thereof
EP0722322B1 (en) 1993-10-01 2001-11-14 Smithkline Beecham Corporation Compounds, compositions and treatment of allergies and inflammation therewith
GB9322828D0 (en) 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
ES2104424T3 (en) 1993-11-26 1997-10-01 Pfizer ISOXAZOLINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS.
PT730587E (en) 1993-11-26 2000-05-31 Pfizer 3-ARIL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS
JP3806144B2 (en) 1993-12-22 2006-08-09 セルテック セラピューティックス リミテッド Trisubstituted phenyl derivatives, their preparation and their use as phosphodiesterase (type IV) inhibitors
GB9326600D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US5508300A (en) 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
ATE178046T1 (en) 1994-02-17 1999-04-15 American Home Prod SUBSTITUTED BIPHENYL DERIVATIVES WITH PHOSPHODIESTERASE INHIBITING EFFECT
CA2143143A1 (en) 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
WO1995027692A1 (en) 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
DE69507197T2 (en) 1994-05-31 1999-05-27 Bayer Ag, 51373 Leverkusen Aminobenzofuryl and thienyl derivatives
GB9410877D0 (en) 1994-05-31 1994-07-20 Bayer Ag Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives
HRP950288A2 (en) 1994-05-31 1997-08-31 Bayer Ag Oxalylamino-benzofuran- and benzothienyl-derivatives
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
ATE217865T1 (en) 1994-06-24 2002-06-15 Euro Celtique Sa COMPOUNDS FOR INHIBITING PHOSPHODIESRERASE IV
KR100381584B1 (en) 1994-07-22 2003-08-21 알타나 파마 아게 Dihydrobenzofuran
EP0779292A4 (en) 1994-08-29 1997-09-24 Yamanouchi Pharma Co Ltd Novel naphthyridine derivative and medicinal composition thereof
US5602110A (en) 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
ATE248153T1 (en) 1994-10-12 2003-09-15 Euro Celtique Sa NEW BENZOXAZOLES
FR2725719B1 (en) 1994-10-14 1996-12-06 Jouveinal Inst Rech DIAZEPINO-INDOLES IV PHOSPHODIESTERASE INHIBITORS
EP0787132A1 (en) 1994-10-20 1997-08-06 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
DE19510965A1 (en) 1995-03-24 1996-09-26 Asta Medica Ag New pyrido / 3,2-e / pyrazinone with anti-asthmatic activity and process for their preparation
TW375612B (en) 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW424087B (en) 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
DE19514568A1 (en) 1995-04-20 1996-10-24 Merck Patent Gmbh Arylalkyl pyridazinones
WO1996035683A1 (en) 1995-05-09 1996-11-14 Nippon Kayaku Kabushiki Kaisha Novel physiologically active na23063 analogues, process for producing the same and use of the same
ES2189871T3 (en) 1995-05-18 2003-07-16 Altana Pharma Ag CICLOHEXIL-DIHIDRO-BENZOFURANOS.
ES2191754T3 (en) 1995-05-18 2003-09-16 Altana Pharma Ag PHENYL-DIHYDROBENZOFURANS.
US5821366A (en) 1995-05-19 1998-10-13 Chiroscience Limited Xanthines and their therapeutic use
AU5772296A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
WO1996036611A1 (en) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772396A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
JPH10147585A (en) 1996-11-19 1998-06-02 Kyowa Hakko Kogyo Co Ltd Oxygen-containing heterocyclic compound
AR004471A1 (en) 1995-05-31 1998-12-16 Smithkline Beecham Corp CYCLOHEXAN-1-OL-4,4-DISSTITUTED COMPOUNDS, USEFUL IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CA2223624C (en) 1995-06-06 2001-02-20 Pfizer Inc. Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
CA2223245C (en) 1995-06-07 2002-05-21 Allen J. Duplantier Catechol diethers derivatives useful as pharmaceutical agents
IL118469A (en) 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
WO1997003967A1 (en) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
CA2227237C (en) 1995-07-26 2005-12-13 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
ES2193252T3 (en) 1995-08-02 2003-11-01 Darwin Discovery Ltd QUINOLONAS AND ITS THERAPEUTIC USE.
US5728845A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
WO1997009345A1 (en) 1995-09-08 1997-03-13 St. Jude Children's Research Hospital Virus protein purification from virosomes
DE19533975A1 (en) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl diazinones
EP0795561B1 (en) 1995-09-29 2002-12-11 Japan Science and Technology Corporation Novel anthracycline compound derivatives and medicinal preparations containing the same
GB9523267D0 (en) 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
DE69620458T2 (en) 1995-12-05 2002-10-02 Darwin Discovery Ltd., Cambridge BENZOFURANE CARBOXAMIDES AND SULPHONAMIDES
CA2238875C (en) 1995-12-15 2003-09-16 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
PT871439E (en) 1996-01-02 2004-08-31 Aventis Pharma Inc SUBSTITUTED HYDROXYLIC ACID COMPOUNDS (ARYLETHYLETHYLRENE ARYLMETHYL OR HETEROYARMETHYL)
DE19601938A1 (en) 1996-01-12 1997-07-17 Schering Ag New phosphodiesterase inhibitors
BR9707233A (en) 1996-01-31 1999-07-20 Byk Gulden Lomberg Chem Fab Phenanthridines
CA2242598A1 (en) 1996-02-21 1997-08-28 John Gary Montana Quinolones and their therapeutic use
EP0882047A1 (en) 1996-02-21 1998-12-09 Darwin Discovery Limited Quinolones and their therapeutic use
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP0889886B1 (en) 1996-03-26 2002-09-18 ALTANA Pharma AG Novel phenanthridines substituted in the 6 position
FR2746800B1 (en) 1996-03-29 1998-06-05 Jouveinal Inst Rech DIAZEPINO-INDOLES PHOSPHODIESTERASE INHIBITORS 4
FR2754260B1 (en) 1996-10-04 1998-10-30 Adir NOVEL SUBSTITUTED DERIVATIVES OF BIPHENYL OR PHENYLPYRIDINE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0912568B1 (en) 1996-05-15 2002-11-20 ALTANA Pharma AG imidazopyridines
JP2000510865A (en) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Quinolinecarboxamides as inhibitors of TNF and PDE-IV
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
JP4017214B2 (en) 1996-06-11 2007-12-05 興和創薬株式会社 5-Phenyl-3-pyridazinone derivatives
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JPH1072415A (en) 1996-06-26 1998-03-17 Nikken Chem Co Ltd 3-anilino-2-cycloalkenone derivatives
DE69709493T2 (en) 1996-06-27 2002-10-31 Pfizer Inc., New York Substituted indazole derivatives
DE19628622A1 (en) 1996-07-16 1998-01-22 Byk Gulden Lomberg Chem Fab New chromene derivatives useful as phosphodiesterase IV inhibitors
DE19628621A1 (en) 1996-07-16 1998-01-22 Byk Gulden Lomberg Chem Fab New 4-substituted benzofuran compounds are phosphodiesterase IV inhibitors
DE69730980T2 (en) 1996-07-31 2006-02-23 Nikken Chemicals Co., Ltd. 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ON DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEY
AU3899097A (en) 1996-08-05 1998-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted aromatic compounds
EP0918746B1 (en) 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutic agents and their use in the reduction of cytokine levels
DE19632549A1 (en) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazines
AU4454597A (en) 1996-08-19 1998-03-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzofuran-4-carboxamides
WO1998008844A1 (en) 1996-08-26 1998-03-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
AU4015497A (en) 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
EP0920426B9 (en) 1996-08-26 2005-04-06 ALTANA Pharma AG New thiazole derivatives with phosphodiesterase-inhibiting effect
CA2264685C (en) 1996-08-27 2002-10-15 Kyoji Noda 2-phenylmorpholin-5-one derivatives and pharmaceutical composition comprising the same
BR9712005A (en) 1996-09-04 1999-08-24 Pfizer Indazole derivatives and their uses as phosphodiesterase (pde) type IV inhibitors and production of tumor necrosis factor (tnf)
DE19636150A1 (en) 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
US5744473A (en) 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
FR2753969B1 (en) 1996-09-27 1998-10-30 Adir NOVEL FLAVON DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP0989129B1 (en) 1996-10-04 2002-12-11 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
CZ288752B6 (en) * 1996-11-11 2001-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine derivatives and pharmaceutical preparation containing thereof
US6054475A (en) 1996-11-20 2000-04-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted dihydrobenzofuran-based phosphodiesterase 4 inhibitors useful for treating airway disorders
ID19155A (en) 1996-12-13 1998-06-18 Tanabe Seiyaku Co PYRIDINES, THEIR PRODUCTS AND THE INTERMEDIETS FOR THE PRODUCTION
HUP0001541A3 (en) 1997-01-15 2001-11-28 Altana Pharma Ag Phthalazinone derivatives and pharmaceutical compositions containing them
DE59814173D1 (en) * 1997-02-28 2008-04-03 Nycomed Gmbh SYNERGISTIC COMBINATION OF PDE INHIBITORS AND ADENYLATE CYCLASE AGONISTS BZW. GUANYLCYCLYSE AGONISTS
ATE248167T1 (en) 1997-03-07 2003-09-15 Altana Pharma Ag TETRAZOLE DERIVATIVES
NZ337698A (en) 1997-04-04 2001-07-27 Pfizer Prod Inc Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases
WO1998055481A1 (en) 1997-06-03 1998-12-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine
KR19990001101A (en) 1997-06-12 1999-01-15 손경식 Catechol amino acid derivatives, preparation methods thereof and pharmaceutical compositions containing the same
DE69808099T2 (en) 1997-07-25 2003-05-15 Altana Pharma Ag SUBSTITUTED 6-ALKYLPHENANTHRIDINE
AU756349B2 (en) 1997-07-25 2003-01-09 Altana Pharma Ag Substituted 6-phenylphenanthridines
ATE260899T1 (en) 1997-07-25 2004-03-15 Altana Pharma Ag NEW TETRAZOLE DERIVATIVES
ES2137113B1 (en) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa NEW DERIVATIVES OF TRIAZOLO-PIRIDAZINAS HETEROCICLICOS.
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
ATE432078T1 (en) * 1997-11-13 2009-06-15 Mowycal Lending Llc SMALL PEPTIDES AND METHODS FOR TREATING ASTHMA AND INFLAMMATION
DE69821530T2 (en) 1997-12-15 2004-12-23 Altana Pharma Ag DIHYDROBENZIFURANE
WO1999031071A1 (en) 1997-12-15 1999-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
US6306869B1 (en) * 1998-05-05 2001-10-23 Byk Gulden Lomberg Chemische Febrik Gmbh N-oxides
JP2002523452A (en) * 1998-08-26 2002-07-30 スミスクライン・ビーチャム・コーポレイション How to treat lung disease
US6303145B2 (en) 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REFERENCE CITED IN WO 2001/013953 *

Also Published As

Publication number Publication date
ATE447952T1 (en) 2009-11-15
HRP20020158B1 (en) 2007-08-31
CA2715683A1 (en) 2001-03-01
HUP0203098A2 (en) 2003-01-28
US20060079539A1 (en) 2006-04-13
NO20020815L (en) 2002-02-19
IL147688A0 (en) 2002-08-14
US20060205806A1 (en) 2006-09-14
BR0013478A (en) 2002-04-30
ZA200201389B (en) 2002-08-21
ES2260043T3 (en) 2006-11-01
AU6701600A (en) 2001-03-19
EA006685B1 (en) 2006-02-24
DK1212089T3 (en) 2006-07-24
CA2381802A1 (en) 2001-03-01
WO2001013953A2 (en) 2001-03-01
NO328340B1 (en) 2010-02-01
SK287231B6 (en) 2010-04-07
IL147688A (en) 2007-09-20
TR200201317T2 (en) 2002-11-21
US7056936B2 (en) 2006-06-06
HK1047244A1 (en) 2003-02-14
KR20020020275A (en) 2002-03-14
PL200923B1 (en) 2009-02-27
SI1212089T1 (en) 2006-08-31
KR100701904B1 (en) 2007-04-02
EP1212089A2 (en) 2002-06-12
NZ517166A (en) 2004-01-30
BRPI0013478B8 (en) 2016-12-27
JP5038568B2 (en) 2012-10-03
CZ302882B6 (en) 2012-01-04
EP1671651B1 (en) 2009-11-11
NO20020815D0 (en) 2002-02-19
CN1370081A (en) 2002-09-18
CZ2002641A3 (en) 2002-08-14
CN1202865C (en) 2005-05-25
EP2193808A1 (en) 2010-06-09
PT1212089E (en) 2006-08-31
CA2381802C (en) 2010-12-07
HK1047244B (en) 2006-10-27
EP1212089B1 (en) 2006-03-22
HU229439B1 (en) 2013-12-30
HRP20020158A2 (en) 2004-02-29
EA200200208A1 (en) 2002-08-29
HUP0203098A3 (en) 2006-07-28
PL356252A1 (en) 2004-06-28
MXPA02001830A (en) 2002-08-12
WO2001013953A3 (en) 2001-09-20
BRPI0013478B1 (en) 2016-12-06
DE60026855D1 (en) 2006-05-11
JP2003507435A (en) 2003-02-25
TR200909479T2 (en) 2012-02-21
SK2552002A3 (en) 2002-06-04
EP1671651A1 (en) 2006-06-21
US20040034087A1 (en) 2004-02-19
DE60043318D1 (en) 2010-01-14
ATE320800T1 (en) 2006-04-15
DE60026855T2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
AU777012B2 (en) Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
US6624181B1 (en) Synergistic combination
EP1482938B1 (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
KR101071798B1 (en) New synergistic combination comprising roflumilast and formoterol
CA2460442A1 (en) Combination of a pde inhibitor and a leukotriene receptor antagonist
AU2002333851A1 (en) Combination of a PDE inhibitor and a leukotriene receptor antagonist

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 24, PAGE(S) 5039-5042 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 67016/00

TC Change of applicant's name (sec. 104)

Owner name: ALTANA PHARMA AG

Free format text: FORMER NAME: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired